<< Back To Search

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
Researchers are testing a new treatment for people who have relapsed multiple myeloma, a type of cancer. The treatment includes a medicine called daratumumab and a chemotherapy drug called pomalidomide. Daratumumab may stop cancer cells from growing and spreading, and pomalidomide may stop cancer cells from dividing or spreading. The researchers hope that this treatment will help control the disease and improve the health of the patients.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab and hyaluronidase-fihj with pomalidomide may help control the disease in patients with relapsed multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?